As Gilead's Trodelvy stumbles in first-line lung cancer, all eyes turn to Merck, AZ and Daiichi rivals
9th June 2026 Uncategorised 0Merck & Co. and Gilead are pulling the plug on the phase 3 Evoke-03 trial evaluating Trodelvy, combined with Keytruda, as a first-line treatment in patients with PD-L1-high non-small cell lung cancer.
More: As Gilead's Trodelvy stumbles in first-line lung cancer, all eyes turn to Merck, AZ and Daiichi rivals
Source: fierce